Search results
Showing 16 to 30 of 141 results for copd
All NICE products on chronic obstructive pulmonary disease. Includes any guidance, advice and quality standards.
myAIRVO2 for the treatment of chronic obstructive pulmonary disease (MIB161)
NICE has developed a medtech innovation briefing (MIB) on myAIRVO2 for the treatment of chronic obstructive pulmonary disease .
This guideline covers assessment of people aged 16 and over with symptoms and signs of acute respiratory infection (bacterial or viral) at first remote or in-person contact with NHS services. It also covers the initial management of any infections. It aims to support healthcare practitioners in making sure that people’s treatment follows the best care pathway. It forms part of a suite of work on virtual wards being undertaken by NICE.
NICE has developed a medtech innovation briefing (MIB) on FreeO2 automatic oxygen titration for chronic obstructive pulmonary disease and respiratory distress syndrome .
Endobronchial nerve ablation for chronic obstructive pulmonary disease (IPG714)
Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.
View recommendations for IPG714Show all sections
Awaiting development [GID-MT608] Expected publication date: TBC
Smoking: smoking status of people with long-term conditions (IND156)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD or asthma, whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM126
Recommendation ID NG115/3 Question Inhaled therapies for people with COPD and asthma- What is the clinical and cost effectiveness of...
Digital platforms to support self-management of asthma : early value assessment
Awaiting development [GID-HTE10063] Expected publication date: TBC
Awaiting development [GID-TA10239] Expected publication date: TBC
NG115/6 Question Diagnosing COPD: - What are the characteristics of people diagnosed with COPD as a result of an...
O2matic PRO 100 for optimising oxygen treatment in respiratory conditions (MIB308)
NICE has developed a medtech innovation briefing (MIB) on O2matic PRO 100 for optimising oxygen treatment in respiratory conditions .
antibiotics for preventing exacerbations:- Which subgroups of people with stable COPD who are at high risk of exacerbations are most...
Smoking: smoking status for people with long-term conditions (IND97)
This indicator covers the percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM38
clinical and cost-effective treatments for pulmonary hypertension in people with COPD? Any explanatory notes(if applicable) N/A Source...